Himaben Gohil, DO, MSc

University at Buffalo

Poster(s):

• P1029 - Semaglutide and Tirzepatide Have the Most Clinical Benefit Compared to Most Weight Loss Medications in Inflammatory Bowel Disease
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM PDT

• P1030 - Evaluating the Key Risk Factors for Crohn’s Disease Flares in a Marginalized Population
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM PDT

• P1031 - Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Comparison of Agent-Specific Outcomes in Type 2 Diabetes and Obese Inflammatory Bowel Disease Populations
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM PDT

• P1931 - Conservative Management of Pneumatosis Intestinalis and Pneumoperitoneum in Patients With Autoimmune Conditions May Be Associated With Improved Clinical Outcomes
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM PDT